SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
作者信息
Mone Pasquale, Ciccarelli Michele, Jankauskas Stanislovas S, Guerra Germano, Vecchione Carmine, Visco Valeria, Santulli Gaetano
机构信息
Department of Medicine and Health Sciences "Vincenzo Tiberio", Campobasso 86100, Italy; Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, USA; Casa di Cura Montevergine, Mercogliano (Avellino), Italy.
Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi (Salerno), Italy.
出版信息
Lancet Healthy Longev. 2024 Sep;5(9):100632. doi: 10.1016/j.lanhl.2024.08.001. Epub 2024 Sep 13.
Abstract
摘要
相似文献
1
SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂：哪种是最佳抗衰弱药物？
Lancet Healthy Longev. 2024 Sep;5(9):100632. doi: 10.1016/j.lanhl.2024.08.001. Epub 2024 Sep 13.
2
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.在台湾，衰弱对 2 型糖尿病患者 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响：一项回顾性、全国性、纵向研究。
Lancet Healthy Longev. 2024 Sep;5(9):100621. doi: 10.1016/j.lanhl.2024.07.004. Epub 2024 Sep 13.
3
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂：终极组合？
Lancet Diabetes Endocrinol. 2024 Aug;12(8):507-508. doi: 10.1016/S2213-8587(24)00183-9. Epub 2024 Jul 8.
4
Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.2型糖尿病中使用钠-葡萄糖协同转运蛋白2抑制剂和/或胰高血糖素样肽-1受体激动剂的肾脏和心血管结局
J Am Coll Cardiol. 2024 Aug 20;84(8):709-711. doi: 10.1016/j.jacc.2024.07.002.
5
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
6
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.根据丹麦 2 型糖尿病和心血管疾病患者虚弱程度启动 SGLT2 抑制剂和 GLP-1 受体激动剂：一项横断面、全国性研究。
Lancet Healthy Longev. 2023 Oct;4(10):e552-e560. doi: 10.1016/S2666-7568(23)00164-2. Epub 2023 Sep 18.
7
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白-2 抑制剂治疗肝移植受者糖尿病。
Diabetes Obes Metab. 2024 Oct;26(10):4261-4272. doi: 10.1111/dom.15769. Epub 2024 Jul 26.
8
Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.德国2型糖尿病成年患者中与使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂相关的区域社会经济剥夺情况
Diabetes Obes Metab. 2024 Sep;26(9):4116-4120. doi: 10.1111/dom.15741. Epub 2024 Jul 9.
9
GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白2抑制剂：协同保护器官
J Am Coll Cardiol. 2023 Aug 8;82(6):526-528. doi: 10.1016/j.jacc.2023.06.005.
10
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.中国医生中胰高血糖素样肽-1 受体激动剂和钠-葡萄糖协同转运蛋白 2 抑制剂的知识差距和处方模式。
Sci Rep. 2024 Aug 7;14(1):18290. doi: 10.1038/s41598-024-69016-z.
引用本文的文献
1
Derivation and Validation of Prediction Models for Prolonged Length of Stay and 30-Day Readmission in Elderly Patients With Type 2 Diabetes Mellitus: A Multicenter Study.2型糖尿病老年患者长期住院和30天再入院预测模型的推导与验证：一项多中心研究
J Diabetes Res. 2025 May 12;2025:3148242. doi: 10.1155/jdr/3148242. eCollection 2025.
2
Frailty incidence by diabetes treatment regimens in older adults with diabetes mellitus in the ASPirin in Reducing Events in the Elderly Study.在“老年人使用阿司匹林减少事件研究”中，糖尿病老年患者不同糖尿病治疗方案的衰弱发生率。
Geroscience. 2025 Mar 17. doi: 10.1007/s11357-025-01598-6.
3
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂：新型抗衰老工具？
Future Cardiol. 2025 Jan;21(1):5-8. doi: 10.1080/14796678.2024.2433381. Epub 2024 Nov 26.
4
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.达格列净在不同血流动力学特征的射血分数降低心衰真实世界人群中的作用：越差越好。
Cardiovasc Diabetol. 2024 Nov 22;23(1):423. doi: 10.1186/s12933-024-02515-5.
本文引用的文献
1
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.在台湾，衰弱对 2 型糖尿病患者 GLP-1 受体激动剂与 SGLT2 抑制剂有效性和安全性的影响：一项回顾性、全国性、纵向研究。
Lancet Healthy Longev. 2024 Sep;5(9):100621. doi: 10.1016/j.lanhl.2024.07.004. Epub 2024 Sep 13.
2
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
3
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.根据 2 型糖尿病患者的虚弱情况比较 SGLT-2 抑制剂、GLP-1 受体激动剂和 DPP-4 抑制剂的心血管有效性和安全性。
Diabetes Care. 2023 Nov 1;46(11):2004-2014. doi: 10.2337/dc23-0671.
4
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.SGLT2 抑制剂在虚弱中的功能和临床重要性：从肾脏到心脏。
Hypertension. 2023 Sep;80(9):1800-1809. doi: 10.1161/HYPERTENSIONAHA.123.20598. Epub 2023 Jul 5.
5
Metabolic Impact of Frailty Changes Diabetes Trajectory.衰弱的代谢影响改变糖尿病病程。
Metabolites. 2023 Feb 16;13(2):295. doi: 10.3390/metabo13020295.
6
The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.钠-葡萄糖共转运蛋白 2 抑制剂在老年患者（≥75 岁）中的真实世界安全性：一项回顾性、药物警戒学研究。
Cardiovasc Diabetol. 2023 Jan 24;22(1):16. doi: 10.1186/s12933-023-01743-5.
7
SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients.恩格列净通过抑制 SGLT2 改善内皮功能并减少线粒体氧化应激：来自衰弱的高血压和糖尿病患者的见解。
Hypertension. 2022 Aug;79(8):1633-1643. doi: 10.1161/HYPERTENSIONAHA.122.19586. Epub 2022 Jun 15.
8
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.恩格列净可改善伴有射血分数保留的心力衰竭的 2 型糖尿病虚弱老年患者的认知障碍。
Diabetes Care. 2022 May 1;45(5):1247-1251. doi: 10.2337/dc21-2434.
9
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
10
Frailty in elderly people.老年人虚弱。
Lancet. 2013 Mar 2;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9. Epub 2013 Feb 8.
Zotero 插件